KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Receivables - Other (2023 - 2025)

Historic Receivables - Other for BioNTech SE (BNTX) over the last 3 years, with Q3 2025 value amounting to $10.4 million.

  • BioNTech SE's Receivables - Other changed N/A to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year change of. This contributed to the annual value of $10.7 million for FY2024, which is 10268.85% up from last year.
  • According to the latest figures from Q3 2025, BioNTech SE's Receivables - Other is $10.4 million.
  • BioNTech SE's 5-year Receivables - Other high stood at $13.1 million for Q1 2024, and its period low was $4.2 million during Q2 2024.
  • In the last 3 years, BioNTech SE's Receivables - Other had a median value of $8.6 million in 2025 and averaged $8.4 million.
  • As far as peak fluctuations go, BioNTech SE's Receivables - Other plummeted by 3462.9% in 2024, and later skyrocketed by 13448.51% in 2025.
  • Quarter analysis of 3 years shows BioNTech SE's Receivables - Other stood at $5.3 million in 2023, then surged by 102.69% to $10.7 million in 2024, then dropped by 2.63% to $10.4 million in 2025.
  • Its Receivables - Other stands at $10.4 million for Q3 2025, versus $9.8 million for Q2 2025 and $10.5 million for Q1 2025.